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(1400 DNA copies/mL), prompting foscarnet initiation. Her MS 
greatly improved after the first week of antiviral therapy. Serum 
HHV-6 PeR became negative and a LP on D+53 revealed a nor- 
mal protein and CSF PCR for HHV-6 had decreased to 110 DNA 
copies/mL. She was changed to maintenance valganciclovir and 
TPE was tapered and discontinued after remittance of her TMA 
and normalization of her MS. hnportantly, HHV-6 reactivation 
must be considered in adult patients undergoing ASCT who 
develop encephalopathy, fevers of unknown origin, rash, or TMA. 
An aggressive pursuit of this diagnosis in the appropriate clinical 
setting is critical given its often fuhninant course in immnnosup- 
pressed patients who are left untreated. 
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AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MULTIPLE 
MYELOMA (MM): ACHIEVEMENT OF CR IS ASSOCIATED WITH 
IMPROVED SURVIVAL 
Kmnar, L/; Kochupillai, ~U; Ga77essan, K~ 1. ALL India bzstitute of
k/ledical ScieJlces, Neu, Delhi, Delhi, II~dia; 2. All flzdia ITzstitztte of 
Medical Sciences, Nezz, Delhi, Delhi, India; 3. All India b~stitute of 
k/leclical Sciences, New Delhi, Delhi, imtia. 
Background : HD-CT  with ASCT is currently used in the treat- 
meat (Tt) of patients (Pts) with advanced MM.  Methods : 50 Pts 
(median age-52 years, range, 26-65) with advanced MM under- 
went T t  with HD melphalan with ASCT (BM -7, PB -43). M:F : 
35:15. All Pts initially had received CT, mean no of CT  cycles 
9.38 (range, I- 36). 30/50 (60%) patients had evidence of chemo- 
sensitive disease at transplant (Tx). Mean interval from diagnosis 
to Tx was 17.5 months (range, 3 to 129). Median no of MNC 
infused was 4. 86 xl0(8)/kg (range, 2 - 10.48). Results : Post -Tx, 
43 / 50 Pts engrafted; median no of days to engraft  (ANC 
(>g00/cmm) was 12 days (range, 9 - 24) & to achieve platelet 
transfusion independence (>20 K) was 13 days (range, 8 - 36). 
Grade III-IV oral mucositis was major non-haematologic toxicity. 
Following Tx, 78% of Pts responded; CR - 29 (58)%, & PR - 
20%. CR rate was higher for Pts with chemo-sensitive dis. ; 20/26 
Pts with PR at Tx achieved CR vs 5/20 Pts with persistentJrefrac- 
to W dis., p<.01. Post Tx, Pts received interferon-alfa (3 mU 3/wl 0 
for one year. Currently, 34/43 Pts (79%) are alive, 17 (39.5%) dis- 
ease-free, 9(21%) Pts have died ; 8 of progressive dis. & 1 of unre- 
lated cause. The  median FU for the whole group is 26 mon. 
(range, 1-144 nmnths). Estimated OS & PFS at 55 months is 58% 
& 34%, respectively. Low Hb (<10g%) (p<.003) & stage B dis. at 
diagnosis affected the survival adversely. Chemo-sensi t ive 
dis.(p<.008) at Tx and achievement of CR post - Tx (<.0001) were 
associated with significantly ilnproved sm-vival. Conclusions: HD 
melphalan with ASCT is an effective Tt  for advanced myeloma .
Achievement of CR is associated with improved survival. 
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REQUIRING MORE THAN TWO APHERESIS PROCEDURES IMPACTS 
ADVERSELY ON OUTCOME OF AUTOLOGOUS PERIPHERAL BLOOD 
STEM CELL TRANSPLANTATION 
Nieder, M.L.; k/lcCrae, E.; Fisher, V.L.; Fox, R.; Creger, R.; Lazavas, 
H.M., O'RioJ'&m, M. Case HZeste'rn Reserve University, Clevelamt, OH. 
Despite improvements in transplantation co-incident with the 
switch from marrow to blood, there remain obstacles to success 
(early relapse, failure to mobilize stenr cells). We reviewed our 
extensive 4 year experience to identify predictive factors for suc- 
cessful engraftment and survival. We wanted to determine if cer- 
tain difficulties encountered uring PBSC acquisition via aphere- 
sis had any affect on eventual engraftment after transplantation. 
We performed 790 apheresis procedures on 274 patients from 
1998-2001 (age range 7 months-69 years). The  majority of 
patients were mobilized with chenmtherapy and GCSF. However, 
a small number of patients received a combination of GM-CSF 
and G-CSF prior to PBSC collection. Of the entire group, 231 
patients (85%) eventually underwent transplantation. 7.3% of the 
patients were not transplanted because of unsuccessful mobiliza- 
tion/steln cell collection. Patients most conmmnly underwent 
transplantation as therapy for leukemia, breast cancer, Hodgldns 
and NonHodgkins Lymphoma and multiple myeloma. Patients 
who needed to undergo only 1 or 2 apheresis procedures (as com- 
pared to those needing 3 or more) had earlier engraftment of 
WBC and platelet counts and fewer infectious complications. 
These data suggest that patients who require more than two 
apheresis procedures prior to autograft should be considered at 
increased risk for complications during transplantation. Perhaps 
information regarding this increased risk should be incorporated 
into patient pre-transplant discussions and consent. 
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ENGRAFTMENT SYNDROME IN AUTOLOGOUS TRANSPLANTATION: A 
FUNCTION OF CD34+ CELL DOSE 
Dmlato, ~I.L.; Saliba, R.k/l.; Aleman, A.; Ippol#i, C.; Gershemon, D.; 
Betha,icow-t, D.; CTaampli,z, R. The University ofTexas k/I.D. Amler- 
solz Cancer Cente*', Hoaston, 7P~(. 
Engraftment syndrome (ES) has been described in the autologous 
transplant setting. Our aim was to determine factors predictive of 
ES in a uniform population. We have analysed 101 patients with 
advanced ovarian cancer receiving high-dose topotecan, melphalan 
and cyclophosphamide with autologous tem cell transplantation. 
Engraftment fever (EF) was the only component of ES observed in 
this group and was defined as onset of ever > 38 ° C within 3 days 
pre and 4 days post engrafnnent. Patients with fever starting prior to 
that or associated with an infection were considered unevaluable (18 
patients). The median age was 50 y (21-67y). The median time to 
ARC >0.5x109 was 9 days (8-11) and to platelets > 100xl09 was 15 
days (10-322). There were no transplant-related deaths. Of  the 83 
evaluable patients 37 (45%) had engraftment fever (38 ° - 39 ° C). 
These patients had received asignificantly higher number of CD34+ 
cells/kg (median 7.7 vs 10.1) p=0.01. Twenty patients (54%) with 
engraftment fever had peripheral blood blasts in the engraftment 
period compared to 13 % for patients without fever p<0.001.54% of 
patients with engraftment fever received methylprednisolone 
emperically, mostly lmg/kg (range 0.5-6.5 mg/kg). Age, prior ther- 
apy, and regimen-related to,city were not associated with a higher 
incidence of EF. The presence of EF had no impact on survival or 
progression-free survival. In conclusion, patients receiving >8- 
10xl 06 CD34+ cells/kg are at increased risk of developing engraft- 
ment fever and ma W will present with circulating blasts on engraft- 
nrent. Whether steroids are advisable remains to be determined. 
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THE EFFECT OF GLUTAMINE ON DISEASE PROGRESSION IN MULTIPLE 
MYELOMA (MM) PATIENTS RECEIVING HIGH-DOSE MELPHALAN 
Crook, if.L; H~lsale1~ko, if.I(.; Myhamt, R.C. H~dter Reed Alvny3/led- 
k'al Ce~ter, lT/ashiJ~gto~z, DC. 
Mucositis, a frequent complication of high-dose therapy, is asso- 
ciated with major morbidity and mortality. Glutamine is one 
agent hat has been shown to protect he gastro-intestinal epitheli- 
um from the toxic effects of chenmtherapy. Although oral gluta- 
mine has been used successfully to prevent transplant related 
mucositis, the potential for glutamine mediated tunmr protection 
has not been systematically investigated. In order to identify any 
possible tumor protective ffect of glutamine in high-dose thera- 
py, we performed a retrospective review of consecutive patients 
who received high-dose therapy with melphalan (200 rag/m2) for 
MM either with or without glutamine. Between July 1997 and 
August 2002, 41 patients were treated at our institution. The first 
17 patients did not receive glutamine prophylaxis. In July 2000, we 
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incorporated glutamine (10 gm po TID starting with t e adminis- 
tration of the preparative regimen) standardly for mucositis pro- 
phylaxis. Twenty-four patients received glutamine. Eleven 
patients were lost to follow up (6 no glutamine, 5glutamine). The 
response rate to transplant in the no glutamine group was 43%, 
compared with 47% in the glutamine group. In the no glutamine 
group, 8/11 patients (73%) were progression free at a median fol- 
low-up of 19 months, compared with i5/19 (79%) in the gfuta- 
mine group at a median follow-up of only 9 months. Interestingly, 
of the patients who relapsed, the median time to relapse was 17 
months in the no glutamine group and only 6 months in the gluta- 
mine group. Our observation is that glutamine at this dose may be 
associated with early relapse and poorer progression-free survival 
(PFS) in MNI patients treated with high-dose melphalan. These 
data support he iTl vitro examination of glutamine in tumor cell 
lines to discern if glutamine abrogates the cytotoxic effects of 
chemotherapy. Future prospective trials should scrutinize 
response rates, PFS, and overall survival in glutamine and non- 
glutamine treated patients especially if higher-doses are utilized. 
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FLUDARABINE PRETREATMENT AND CD34+ YIELDS IN NON- 
HODGKINS LYMPHOMA STEM CELL PATIENTS 
PaivaJms, N J; Beve~'idge, M/ ;  L~t'madm,, if.e: StJeridml, ZVI.2; To~'loM, 
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Background: Previous chemotherapy, radiation and bone marrow 
infiltration by malignancy are predictors of poor stem cell yield in 
patients undergoing peripheral blood stem cell harvests for autolo- 
gous stem cell transplantation (SCT). Prior treatment with Fludara- 
bine is thought to adversely affect yields as well. We have examined 
our institution's data to determine whether this is an accurate obser- 
vation. Methods: Apheresis records from patients with Non- 
Hodgkins Lymphoma (NHL) undergoing SCT were reviewed 
(N=43). The patient population ncluded 35 patients who received 
non-fludarabine containing chemotherapy regimens; with 4 patients 
of the non-fludarabine population receiving radiation and 
chemotherapy. Eight (8) patients had received chemotherapy that 
included 3 to 6 cycles of FND (average 3.8). Patients were uniform- 
ly mobilized with 10mcg/kg/d of Granulocyte Colony Stimulating 
Factor (G-CSF). High volume (40L) apheresis was performed for 1- 
4 days with a collection goal of 5 X10^6 CD34/kg ideal body 
weight. Data were analyzed using non-parametric one-way analyses 
of variance. Results: Patients who had received previous chemother- 
apy with no fludarabine yielded a median of 5.8 XI0^6 CD34 cells 
(n=31; range 2.7-11.6 X10A6). Patients who had previously received 
three to six cycles of FND were also able to meet he apheresis goal 
for collection, yielding a median of 5.0 XIOA6 CD34 cells/kg (n=8; 
range 4-13.1 X10^6). Patients who had received prior non-fludara- 
bine chemotherapy and radiation were not generally abIe to meet 
the apheresis target, and had the lowest median yield of CD34 cells, 
(3.1 XIOA6 CD 34 cells/kg; n=4; range 0.9-5 X10A6). Conclusion: 
Pretreatment with 6 or fewer cycles of FND had no statistically sig- 
nificant adverse ffect on the total yield of CD34 cells. Patients 
treated with FND did not require additional apheresis procedures, 
as compared to non-fludarabine regimen treated patients. As expect- 
ed, increased cycles of prior chemotherapy, prior radiation, and 
increasing age were all associated with lower total CD34 yields and 
additional apheresis procedures in order t0.reach the target dose. 
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THE ADMINISTRATIVE CHALLENGE IN THE DEVELOPMENT OF A 
POINT OF SERVICE CLINIC FOR POST BLOOD AND MARROW TRANS- 
PLANTATION PATIENTS 
Actometto, D.L.; Stray, s.J.; Neumam~, 07.; Ippoliti, C.; SoremeJ~, S. 
BAqT Ceme'v, UT 2VID ATMersom Hoztstmz, TX. 
Todays health care cltinate and advancements in Blood and 
Marrow Transplantation have challenged the outpatient adminis- 
trative staff to develop innovative strategies in caring for higher 
acuity patients. Autologus Transplantation patients are frequently 
discharged from the hospital immediately following chemotherapy 
for mobilization, or soon after engraftment. The challenge was to 
integrate this patient population into the outpatient clinic. These 
early discharges challenge the outpatient staff to provide quality 
care while meeting the needs of all patients. The rationale for the 
development of the Fast Track Clinic is to perform laboratory 
testing and patient evaluation by a bone marrow transplant urse, 
APN, and clinical pharmacist in a familiar environment. Specifi- 
cally identified treatment eeds are performed in this clinical area 
while long-term fluid infusion, and blood product ransfllsion are 
transitioned to other clinical areas. The Administrative challenges 
in developing this clinical area, included space feasibility, room 
utilization, staff education/skills, equipment/supply issues, finan- 
cial issues, and staff buy-in. Space feasibility was evaluated by a 
room utilization study indicating low usage in the morning hours. 
The staff educator provided intense training on pump usage, CVC 
care, and IV drug administration. Strategies were planned in col- 
laborative multidisciplinary meetings with the administrative and 
clinical staff to provide a sense of ownership in developing this 
process. One advantage of the fast track clinic is that patients are 
followed by the same personnel from initial consultation through- 
out the transplant journey. Another impact of the implementation 
of the fast track clinic is the enhancement of the RNs technical, 
critical thinking, and problem solving skills. Patient satisfaction 
surveys and comment cards are obtained on a monthly basis, 
reviewed for possible improvements, and demonstrate a high level 
of satisfaction regarding care of the patient. 
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SAFETY OF RITUXIMAB FOLLOWING AUTOLOGOUS STEM CELL 
TRANSPLANT 
Calderol~, N. 1, JohJ~, 14S. l; Loscal:o, a7.1; Bayer, R.I 
1. Hematology/Omology, No*~,O Shorn UJ~iversity Hospital Manhasset, 
NK," 2. North Shorn UTffversity Hospital, MaT~hasset, NY; 3. North 
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The use of Rituximab for post-transplant immunolnodulation 
has revealed promising effects. Published ata demonstrates that 
administration of Rituximab following autologous peripheral 
stem cell transplant causes rapid depletion of CD20+ cells with- 
out increase in infection. Studies conducted in patients with fol- 
licular lymphoma nd mantle cell lymphoma suggest hat this 
approach is feasible and safe, and appears effective in eliminat- 
ing minimal residual disease leading to high rates of durable 
remission. Common reported side effects associated with Ritux- 
imab administration i clude fever and chills, bronchospasm, 
angioedema, hypersensitivity reactions a d tmnor lysis syn- 
drome. Transient cytopenias are usually not severe. Less com- 
mon adverse events include hypogammaglobulinemia, cardiac 
arwthmias, grade 4 cytopenias, serum sickness and vasculitis. 
The infusion of the antibody during immune reeonstitution 
after autograft may be associated with adverse vents not cmn- 
monly seen in the pre-transplant setting. We reviewed 7 
patients who received Rituximab consolidation following 
APSCT and documented the incidence of cytopenias and any 
associated adverse events. Two patients had APSCT for trans- 
formed follicular lymphoma, tour patients had diffuse large cell 
lymphoma nd one had mantle cell lymphoma. Adverse events 
included prolonged thrombocytopenia and neutropenia and one 
patient developed acute congestive heart failure with diffuse 
myocardial hypokinesis and severe tricuspid regurgitation 
reversible after treatment with steroids and inotropes. Five 
patients are in complete remission with a median follow up of 
45 weeks and two patients recurred shortly after completing Rit- 
u~mab consolidation. The administration of Rituximab follow- 
i ng APSCT may be associated with improved progression-free 
survival and appears to be feasible with careful observation. 
Based on this retrospective r view we suspect hat the adminis- 
tration of Rituximab in the post-transplant setting may be asso- 
ciated with uncommon and serious side effects such as acute 
heart failure and moderate to severe thronthocytopenia and neu- 
tropenia observed even after complete count recovery post- 
transplant. 
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